Top 5 women's health headlines you missed in June 2025

Top 5 women's health headlines you missed in June 2025 | Image Credit: © sebra - stock.adobe.com.

June 2025 delivered pivotal updates across the field of women’s health, spanning clinical guidance, therapeutic innovation, policy statements, and new research insights.

From ACOG’s condemnation of violence against reproductive health providers to promising trial data on managing vasomotor symptoms and recurrent bacterial vaginosis, this month’s developments reflect both the clinical and societal forces shaping OB/GYN practice today. Additional highlights include updated AAP recommendations on adolescent contraceptive care and new findings linking ADHD to increased risk of premenstrual dysphoric disorder.

In this monthly roundup, Contemporary OB/GYN summarizes the most significant clinical findings, expert commentary, and policy developments from June 2025.

Click on each headline below for full coverage and analysis.

1. Elinzanetant found to reduce VMS from endocrine therapy for breast cancer

A phase 3 trial published in the New England Journal of Medicine found that elinzanetant significantly reduced moderate-to-severe vasomotor symptoms in women receiving endocrine therapy for hormone receptor–positive breast cancer. Among the 474 participants, those receiving elinzanetant reported up to 3.5 fewer daily hot flash episodes by week 4 compared to placebo. Improvements in sleep and menopausal quality of life were also greater in the elinzanetant group. These findings address a critical need, as vasomotor symptoms often undermine adherence to endocrine therapy, potentially affecting long-term cancer outcomes.

2. Secnidazole shows promise for recurrent BV treatment in new clinical trial

New data presented at the 2025 ACOG Annual Clinical and Scientific Meeting support the long-term use of secnidazole oral granules for recurrent bacterial vaginosis (BV), a condition affecting nearly 1 in 3 reproductive-aged women in the U.S. In a small trial, once-weekly 2 g doses showed comparable or improved efficacy to CDC-recommended suppressive regimens. Lead investigator Chemen M. Neal, MD, emphasized the potential for simplified dosing to improve adherence and reduce recurrence. The findings also underscore the need for accurate diagnosis and sustained management of BV, which carries both physical and psychosocial burdens.

3. ACOG condemns violence against reproductive health care providers

In a joint statement, ACOG president Steven J. Fleischman, MD, and CEO Sandra E. Brooks, MD, condemned recent acts of violence targeting reproductive health care providers, including a bombing at a Minnesota fertility clinic and online harassment of clinicians. The statement, released following the 2025 ACOG Annual Clinical and Scientific Meeting, underscored the escalating risks ob-gyns face for delivering comprehensive reproductive care. Citing long-standing patterns of ideologically motivated violence, ACOG called for strengthened protections under policies like the Freedom of Access to Clinic Entrances Act and urged political leaders to oppose threats against providers.

4. AAP issues updated guidance on contraception for adolescents

The American Academy of Pediatrics updated its guidance on adolescent contraceptive care, urging pediatricians to provide developmentally appropriate, confidential counseling and access to the full spectrum of contraceptive methods. Published in the July 2025 issue of Pediatrics, the policy emphasizes equity, autonomy, and shared decision-making. The AAP highlights the need for proactive engagement given persistent gaps in contraceptive use among teens and calls for expanded access through telehealth and school-based care. Pediatricians are also encouraged to integrate contraception discussions with broader sexual health care, including STI screening and HPV vaccination.

5. ADHD linked to higher risk of premenstrual dysphoric disorder

Women with ADHD may face a significantly higher risk of premenstrual dysphoric disorder (PMDD), according to new findings published in the British Journal of Psychiatry. Using survey data from U.K. participants, researchers found PMDD symptoms were over three times more likely in women with ADHD, and risk was even higher when anxiety or depression was also present. PMDD was identified in 31.4% of those with ADHD versus 9.8% of those without. The study’s authors called for increased screening and a better understanding of how hormonal changes affect women with ADHD to address diagnostic disparities.